Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies.

@article{Gilbert2016ImpactOA,
  title={Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies.},
  author={Richard E Gilbert and Matthew R. Weir and Paola Fioretto and Gordon T. Law and Mehul Desai and Irina Kline and Wayne Shaw and Gary E Meininger},
  journal={Canadian journal of diabetes},
  year={2016},
  volume={40 3},
  pages={
          247-57
        }
}
OBJECTIVE Reduced efficacy has been reported in the elderly; it may be a consequence of an age-dependent decline in estimated glomerular filtration rate (eGFR) rather than ageing per se. We sought to determine the impact of these 2 parameters, as well as sex and baseline body mass index (BMI), on the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in people with type 2 diabetes. METHODS Data were pooled from 6 randomized, double-blind, placebo-controlled… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS

Canagliflozin: A Review in Type 2 Diabetes

VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.

  • The Journal of clinical endocrinology and metabolism
  • 2019
VIEW 3 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Efficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes

B Neal, V Perkovic, D de Zeeuw
  • Diabetes Care 2015;38:403–
  • 2015
VIEW 2 EXCERPTS

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55 to 80 years with type 2 diabetes

B Bode, K Stenlöf, S Harris
  • Diabetes Obes Metab 2015;17:294–303
  • 2015
VIEW 1 EXCERPT

Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: Findings from the 52-week CANTATA-M study

K Stenlöf, WT Cefalu, KA Kim
  • Curr Med Res Opin
  • 2014